Should I buy or sell Protagonist Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares. View PTGX analyst ratings or view top-rated stocks .

What is Protagonist Therapeutics' stock price target for 2024?

4 brokerages have issued 1 year price targets for Protagonist Therapeutics' stock. Their PTGX share price targets range from $32.00 to $38.00. On average, they predict the company's share price to reach $35.25 in the next twelve months. This suggests a possible upside of 93.6% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts .

How have PTGX shares performed in 2023?

Protagonist Therapeutics' stock was trading at $10.91 at the beginning of the year. Since then, PTGX shares have increased by 66.9% and is now trading at $18.21. View the best growth stocks for 2023 here .

When is Protagonist Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our PTGX earnings forecast .

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its earnings results on Thursday, November, 2nd. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.10.

What ETF holds Protagonist Therapeutics' stock ?

Invesco Dorsey Wright Healthcare Momentum ETF holds 129,690 shares of PTGX stock, representing 1.50% of its portfolio.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV) , Viking Therapeutics (VKTX) , ImmunoGen (IMGN) , SCYNEXIS (SCYX) , Energy Transfer (ET) , Strongbridge Biopharma (SBBP) , Verastem (VSTM) , Dynavax Technologies (DVAX) , Novavax (NVAX) and Sorrento Therapeutics (SRNE) .

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Kynam Capital Management LP (3.15%), Braidwell LP (1.92%), 683 Capital Management LLC (1.27%), Adage Capital Partners GP L.L.C. (1.21%), Northern Trust Corp (0.98%) and Hsbc Holdings PLC (0.96%). Insiders that own company stock include David Y Liu , Dinesh V Ph D Patel and Sarah B Noonberg. View institutional ownership trends .

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Protagonist Therapeutics Stock Price, News & Analysis (NASDAQ:PTGX)

$18.21

+0.52 (+2.94%)

(As of 11/30/2023 ET)

Compare

Today's Range: $17.91
▼
$18.68
50-Day Range: $14.05
▼
$18.21
52-Week Range: $7.34
▼
$30.10

Volume: 447,136 shs
Average Volume: 1.10 million shs
Market Capitalization: $1.05 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $35.25

Protagonist Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 93.6% Upside
$35.25 Price Target
Short Interest: Healthy
6.33% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.76) to ($2.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

626th out of 949 stocks

Pharmaceutical Preparations Industry

296th out of 439 stocks

3.5

Analyst's Opinion

Consensus Rating
Protagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.25, Protagonist Therapeutics has a forecasted upside of 93.6% from its current price of $18.21.
Amount of Analyst Coverage
Protagonist Therapeutics has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.33% of the outstanding shares of Protagonist Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Protagonist Therapeutics has a short interest ratio ("days to cover") of 5.7.
Change versus previous month
Short interest in Protagonist Therapeutics has recently decreased by 7.36%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Protagonist Therapeutics does not currently pay a dividend.
Dividend Growth
Protagonist Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PTGX.

2.7

News and Social Media Coverage

News Sentiment
Protagonist Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Protagonist Therapeutics this week, compared to 2 articles on an average week.
Search Interest
19 people have searched for PTGX on MarketBeat in the last 30 days. This is an increase of 533% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Protagonist Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.00% of the stock of Protagonist Therapeutics is held by insiders.
Percentage Held by Institutions
98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Protagonist Therapeutics are expected to decrease in the coming year, from ($1.76) to ($2.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Protagonist Therapeutics is -6.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Protagonist Therapeutics is -6.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Protagonist Therapeutics has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Protagonist Therapeutics Stock (NASDAQ:PTGX)

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PTGX Stock News Headlines

November 27, 2023 | finance.yahoo.com

Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib

November 16, 2023 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Reports Granting of Inducement Awards

December 1, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 16, 2023 | markets.businessinsider.com

Protagonist Therapeutics Earns ‘Buy’ Rating on Strength of Drug Pipeline and Potential Royalties

November 9, 2023 | finance.yahoo.com

Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)

November 9, 2023 | finance.yahoo.com

Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect?

November 4, 2023 | finance.yahoo.com

Protagonist Therapeutics Inc (PTGX) Reports Q3 2023 Financial Results

November 4, 2023 | markets.businessinsider.com

Protagonist Therapeutics’ Promising Future: Psoriasis Drug Development and Potential Blockbuster Market Opportunities

December 1, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 3, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Protagonist Therapeutics

November 2, 2023 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 2, 2023 | finance.yahoo.com

Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 1, 2023 | finance.yahoo.com

Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis

November 1, 2023 | finance.yahoo.com

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

October 31, 2023 | benzinga.com

Protagonist Therapeutics Stock (NASDAQ:PTGX), Analyst Ratings, Price Targets, Predictions

October 30, 2023 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors

October 30, 2023 | finance.yahoo.com

Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors

October 10, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Ventyx Biosciences (VTYX)

October 10, 2023 | markets.businessinsider.com

Protagonist Therapeutics’ Promising Drug JNJ-2113: A Potential Market Leader and Revenue Booster

October 9, 2023 | markets.businessinsider.com

Promising Clinical Trials and Revenue Potential Propel Buy Rating for Protagist Therapeutics

October 9, 2023 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications

October 9, 2023 | finance.yahoo.com

Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications

September 26, 2023 | msn.com

JP Morgan Maintains Protagonist Therapeutics (PTGX) Overweight Recommendation

September 5, 2023 | finance.yahoo.com

Protagonist Therapeutics to Present at Upcoming Investor Conferences

August 9, 2023 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Receives $34 Million from Warrant Exercises

August 9, 2023 | finance.yahoo.com

Protagonist Receives $34 Million from Warrant Exercises

August 4, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), Dynavax (DVAX)

See More Headlines

Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PTGX
CUSIP: N/A
CIK: 1377121
Web: www.protagonist-inc.com
Phone: (510) 474-0170
Fax: N/A
Employees: 111
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $35.25
High Stock Price Target: $38.00
Low Stock Price Target: $32.00
Potential Upside/Downside: +93.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-127,390,000.00
Net Margins: N/A
Pretax Margin: -16,319.91%
Return on Equity: -54.66%
Return on Assets: -49.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.66
Quick Ratio: 11.66

Sales & Book Value

Annual Sales: $26.58 million
Price / Sales: 39.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.24 per share
Price / Book: 3.48

Miscellaneous

Outstanding Shares: 57,680,000
Free Float: 54,794,000
Market Cap: $1.05 billion
Optionable: Not Optionable
Beta: 1.85

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Dinesh V. Patel Ph.D. (Age 66)
CEO, President, Secretary & Director
Comp: $883.46k
Dr. Suneel K. Gupta Ph.D. (Age 65)
Chief Development Officer
Comp: $640.89k
Dr. Mark Smythe Ph.D. (Age 58)
Founder & VP Technology
Mr. Asif Ali (Age 49)
Executive VP & Chief Financial Officer
Mr. Mohammad Masjedizadeh Ph.D.
Executive VP & Chief Technical Officer
Mr. Matthew M. Gosling (Age 52)
Executive VP & General Counsel
Ms. Carena Spivey
Senior Vice President of Human Resources
Dr. Ashok Bhandari Ph.D. (Age 59)
Executive VP & Chief Drug Discovery and Preclinical Development Officer
Dr. Scott Eric Plevy M.D.
Executive VP & Therapeutic Head of Gastroenterology
Mr. Carter J. King (Age 52)
Senior Vice President of Business Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PTGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings or view top-rated stocks.
What is Protagonist Therapeutics' stock price target for 2024?: 4 brokerages have issued 1 year price targets for Protagonist Therapeutics' stock. Their PTGX share price targets range from $32.00 to $38.00. On average, they predict the company's share price to reach $35.25 in the next twelve months. This suggests a possible upside of 93.6% from the stock's current price.
View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts.
How have PTGX shares performed in 2023?: Protagonist Therapeutics' stock was trading at $10.91 at the beginning of the year. Since then, PTGX shares have increased by 66.9% and is now trading at $18.21.
View the best growth stocks for 2023 here.
When is Protagonist Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our PTGX earnings forecast.
How were Protagonist Therapeutics' earnings last quarter?: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its earnings results on Thursday, November, 2nd. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.10.
What ETF holds Protagonist Therapeutics' stock ?: Invesco Dorsey Wright Healthcare Momentum ETF holds 129,690 shares of PTGX stock, representing 1.50% of its portfolio.

What other stocks do shareholders of Protagonist Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).
When did Protagonist Therapeutics IPO?: (PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.
Who are Protagonist Therapeutics' major shareholders?: Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Kynam Capital Management LP (3.15%), Braidwell LP (1.92%), 683 Capital Management LLC (1.27%), Adage Capital Partners GP L.L.C. (1.21%), Northern Trust Corp (0.98%) and Hsbc Holdings PLC (0.96%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel and Sarah B Noonberg.
View institutional ownership trends.
How do I buy shares of Protagonist Therapeutics?: Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PTGX) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial